glp-1 drug news today 2025 obesity october Outlook for obesity in 2025: more than a transition year Patients taking an experimental oral

Its important to know youre not alone in this experience, and there are ways to manage it while continuing your treatment

Gut-brain axis and neurodegeneration: mechanisms and therapeutic potentials

GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice are Mediated via the GLP-1 Receptor and Not Associated With RET Activation

Semaglutide is marketed under three brand names to distinguish different indications and formulations: Ozempic (injectable for diabetes), Wegovy (injectable for obesity), and Rybelsus (oral for diabetes)

and Campbell R

Phase 1: initiation and early escalation (weeks 1 to 8) During the first weeks, heart rate changes are generally minimal at starting doses